About Us

Amylyx is an clinical stage pharmaceutical company dedicated to providing innovative, disease-modifying solutions for neurodegenerative diseases.

Our Team

CEO and Founder: Joshua Cohen
President and Founder: Justin Klee
Vice President, Research: Kent Leslie
Chairman of SAB: Dr. Rudolph Tanzi
Director: Steve Chubb
Director: George Milne
Director: Wally Gilbert

Latest News

Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis

Cambridge, MA
September 19, 2017

Learn More